AntiBodyChain
Medical Lab Supplies

PRODUCT INFORMATION

Anti-Vedolizumab antibody

Anti-Vedolizumab is a chimeric rabbit/mouse antibody that specifically targets the human therapeutic antibody Vedolizumab. It has rabbit variable domains and mouse constant domains, mainly binding to free Vedolizumab in samples.

Article number	M9265
Product group	Recombinant Antibody
Techique	ELISA

AntiBodyChain
www.antibodychain.com
order.handling@antibodychain.com
+31(0) 43 2010 660
Wim Duisenbergplantsoen 31
6221SE
Maastricht

Sanquin · UMC Utrecht · Amsterdam UMC Universitair Medische Centra · LUMC Leids Universitair Medisch Centrum · Maastricht UMC+ · Radboud umc university medical center

Technical information sheet

Plesmanlaan 125
1066 CX Amsterdam
P.O. Box 9190
1006 AD Amsterdam
The Netherlands

Anti-Vedolizumab antibody M9265

For research use only

Application

Anti-Vedolizumab is a chimeric rabbit/mouse anti-idiotypic antibody that specifically targets the human therapeutic antibody Vedolizumab. The antibody consists of rabbit variable domains and mouse constant domains. The recombinant antibody binds mainly to free Vedolizumab in samples.

Vedolizumab is a human IgG1/kappa antibody, recognising the α4β7 integrin, which is expressed by immune cells to mediate migration to the intestine.[1, 2]

Anti-Vedolizumab antibody has been evaluated in ELISA, other techniques need to be validated by the user. It is recommended to test the antibody by titration of the product in the used technique, using appropriate negative/positive controls.



Figure 1: *Titration of Vedolizumab to create a pharmacokinetic (PK) curve in bridging ELISA. Anti-Vedolizumab antibody was used as capture (0.25µg/ml) and detection (0.125 µg/ml) antibody in sandwich assay format, as described previously. [3] VDZ= Vedolizumab*

References

1 European Medicines Agency (EMA). Entyvio (vedolizumab). https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio. 2023.

2 Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol. 2021; **9**.

3 Großerichter-Wagener C, Kos D, van Leeuwen A, Dijk L, Jeremiasse J, Loeff FC et al. Biased anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics. MAbs 2020; **12**. PMID:32887534.